Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.54 |
| ▸ | WDR5 | P61964 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21595770 | 0.95 | MAPT (0.56) | MAPTSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL19828150 | 0.85 | L3MBTL4 (0.65) | MAPTSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL13503080 | 0.83 | ALDH1A1 (0.56) | MAPTSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL11413525 | 0.81 | S1PR4 (0.66) | MAPTTDP1S1PR4 | |
| SCHEMBL5477791 | 0.80 | ALDH1A1 (0.68) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL10918358 | 0.80 | HPGD (0.58) | MAPTSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL11423354 | 0.80 | MAPT (0.52) | MAPTSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL5736337 | 0.80 | LMNA (0.54) | MAPTSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL10062742 | 0.80 | HPGD (0.59) | MAPTSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL7237501 | 0.80 | MAPT (0.58) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168484-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-09-14 | — | — | WO | disclosed |
| EP-2280929-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RASAGILINE | GENERICS UK LTD (GB) | 2018-01-31 | — | — | EP | disclosed |
| US-9694014-B2 | Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors | UNIVERSITA DEGLI STUDI DI PADOVA (IT) | 2017-07-04 | — | — | US | disclosed |
| US-9682944-B2 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | PIRAMAL IMAGING SA (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9675620-B2 | MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170029371-A1 | MAO INHIBITORS AND THEIR CONJUGATES AS THERAPEUTICS FOR THE TREATMENT OF BRAIN CANCER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-02-02 | — | — | US | disclosed |
| US-20110184071-A1 | PROCESS FOR THE PREPARATION OF AMINES | GENERICS [UK] LIMITED | 2011-07-28 | — | — | US | disclosed |
| WO-2009147432-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AMINES | GENERICS [UK] LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029371-A1 | MAO INHIBITORS AND THEIR CONJUGATES AS THERAPEUTICS FOR THE TREATMENT OF BRAIN CANCER | MAOA, MAOB, COMT | MAPT 467/4885SMN1; SMN2 1031/4885KDM4E 339/4885 |
| US-20110184071-A1 | PROCESS FOR THE PREPARATION OF AMINES | RAB1A, RAB35, RAB7A | MAPT 989/4885SMN1; SMN2 980/4885KDM4E 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.